270 related articles for article (PubMed ID: 17876052)
1. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.
Kim W; Yoon JH; Jeong JM; Cheon GJ; Lee TS; Yang JI; Park SC; Lee HS
Mol Cancer Ther; 2007 Sep; 6(9):2554-62. PubMed ID: 17876052
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition.
Yu SJ; Yoon JH; Yang JI; Cho EJ; Kwak MS; Jang ES; Lee JH; Kim YJ; Lee HS; Kim CY
J Bioenerg Biomembr; 2012 Feb; 44(1):101-15. PubMed ID: 22350012
[TBL] [Abstract][Full Text] [Related]
3. Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model.
Cho EJ; Yu SJ; Kim K; Cho H; Cho YY; Lee YB; Lee JH; Kim YJ; Youn H; Yoon JH
J Bioenerg Biomembr; 2019 Apr; 51(2):121-129. PubMed ID: 30746618
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis.
Yu SJ; Yoon JH; Lee JH; Myung SJ; Jang ES; Kwak MS; Cho EJ; Jang JJ; Kim YJ; Lee HS
Acta Pharmacol Sin; 2011 Jul; 32(7):912-20. PubMed ID: 21666701
[TBL] [Abstract][Full Text] [Related]
5. [Expression of hexokinase-II gene in human colon cancer cells and the therapeutic significance of inhibition thereof].
Peng QP; Liang HJ; Zhou Q; Zhou JM; Fu XL; Zhong DP
Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1058-62. PubMed ID: 17672972
[TBL] [Abstract][Full Text] [Related]
6. Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma.
Yoo JJ; Yu SJ; Na J; Kim K; Cho YY; Lee YB; Cho EJ; Lee JH; Kim YJ; Youn H; Yoon JH
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875800
[TBL] [Abstract][Full Text] [Related]
7. Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2.
Xu D; Jin J; Yu H; Zhao Z; Ma D; Zhang C; Jiang H
J Exp Clin Cancer Res; 2017 Mar; 36(1):44. PubMed ID: 28320429
[TBL] [Abstract][Full Text] [Related]
8. 3-Bromopyruvic acid, a hexokinase II inhibitor, is an effective antitumor agent on the hepatoma cells : in vitro and in vivo findings.
Gong L; Wei Y; Yu X; Peng J; Leng X
Anticancer Agents Med Chem; 2014 Jun; 14(5):771-6. PubMed ID: 24738957
[TBL] [Abstract][Full Text] [Related]
9. Effect of the antitumoral alkylating agent 3-bromopyruvate on mitochondrial respiration: role of mitochondrially bound hexokinase.
Rodrigues-Ferreira C; da Silva AP; Galina A
J Bioenerg Biomembr; 2012 Feb; 44(1):39-49. PubMed ID: 22322891
[TBL] [Abstract][Full Text] [Related]
10. Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells : ROS-mediated cell death by 3-BrPA.
Kim JS; Ahn KJ; Kim JA; Kim HM; Lee JD; Lee JM; Kim SJ; Park JH
J Bioenerg Biomembr; 2008 Dec; 40(6):607-18. PubMed ID: 19067133
[TBL] [Abstract][Full Text] [Related]
11. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.
Kim W; Yoon JH; Kim JR; Jang IJ; Bang YJ; Kim YJ; Lee HS
Cancer Chemother Pharmacol; 2009 Aug; 64(3):497-507. PubMed ID: 19096848
[TBL] [Abstract][Full Text] [Related]
12. 3-Bromopyruvate Attenuates Experimental Pulmonary Hypertension via Inhibition of Glycolysis.
Zhang YL; Zhang R; Shen YF; Huang KY; He YY; Zhao JH; Jing ZC
Am J Hypertens; 2019 Mar; 32(4):426-432. PubMed ID: 30561502
[TBL] [Abstract][Full Text] [Related]
13. 3-Bromopyruvate regulates the status of glycolysis and BCNU sensitivity in human hepatocellular carcinoma cells.
Sun X; Sun G; Huang Y; Hao Y; Tang X; Zhang N; Zhao L; Zhong R; Peng Y
Biochem Pharmacol; 2020 Jul; 177():113988. PubMed ID: 32330495
[TBL] [Abstract][Full Text] [Related]
14. Ginsenoside Rg5 increases cardiomyocyte resistance to ischemic injury through regulation of mitochondrial hexokinase-II and dynamin-related protein 1.
Yang YL; Li J; Liu K; Zhang L; Liu Q; Liu B; Qi LW
Cell Death Dis; 2017 Feb; 8(2):e2625. PubMed ID: 28230856
[TBL] [Abstract][Full Text] [Related]
15. Separate and concurrent use of 2-deoxy-D-glucose and 3-bromopyruvate in pancreatic cancer cells.
Xiao H; Li S; Zhang D; Liu T; Yu M; Wang F
Oncol Rep; 2013 Jan; 29(1):329-34. PubMed ID: 23076497
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor activity of 3-bromopyruvate in combination with rapamycin in vivo and in vitro.
Zhang Q; Pan J; Lubet RA; Komas SM; Kalyanaraman B; Wang Y; You M
Cancer Prev Res (Phila); 2015 Apr; 8(4):318-26. PubMed ID: 25644152
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model.
Park HS; Chung JW; Jae HJ; Kim YI; Son KR; Lee MJ; Park JH; Kang WJ; Yoon JH; Chung H; Lee K
Korean J Radiol; 2007; 8(3):216-24. PubMed ID: 17554189
[TBL] [Abstract][Full Text] [Related]
18. Astragaloside IV reduces neuronal apoptosis and parthanatos in ischemic injury by preserving mitochondrial hexokinase-II.
Li Y; Yang Y; Zhao Y; Zhang J; Liu B; Jiao S; Zhang X
Free Radic Biol Med; 2019 Feb; 131():251-263. PubMed ID: 30502455
[TBL] [Abstract][Full Text] [Related]
19. Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists.
Ganapathy-Kanniappan S; Kunjithapatham R; Torbenson MS; Rao PP; Carson KA; Buijs M; Vali M; Geschwind JF
Radiology; 2012 Mar; 262(3):834-45. PubMed ID: 22357885
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.
Pereira da Silva AP; El-Bacha T; Kyaw N; dos Santos RS; da-Silva WS; Almeida FC; Da Poian AT; Galina A
Biochem J; 2009 Feb; 417(3):717-26. PubMed ID: 18945211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
